Overview and Future Potential of Fast Dissolving Buccal Films as Drug Delivery System for Vaccines

Authors

  • Mohammad Nasir Uddin College of Pharmacy, Larkin University, Miami, FL, USA.
  • Amanda Allon College of Pharmacy, Larkin University, Miami, FL, USA.
  • Monzurul A Roni College of Medicine, University of Illinois, Peoria, IL; School of Pharmacy, Wingate University, Wingate, NC, USA.
  • Samir Kouzi College of Medicine, University of Illinois, Peoria, IL; School of Pharmacy, Wingate University, Wingate, NC, USA.

DOI:

https://doi.org/10.18433/jpps30528

Abstract

Vaccination is considered one of the most successful public health interventions of the modern era. Vaccines are categorized based on the antigen used, delivery system and the route of administration. Traditional vaccines are produced from the dead, attenuated or inactivated pathogens that cause disease. However, newly developed vaccines are DNA based, liposome based, and virus like particle (VLP) based which are more effective and specific to some malignant diseases. The delivery system of vaccines has been advanced along with time as well. New delivery systems such as nanoparticles, liposomes, or cells (for DNA) has been proven to develop a more efficient vaccine. Most vaccines are administered via intramuscular (IM), subcutaneous (SQ) or oral (PO) route. However, these routes of administration have limitations and side effects. An alternative route could be oral cavity administration such as buccal or sublingual administration using film dosage form as delivery vehicle. In this article, we thoroughly reviewed the possibility of developing a quickly soluble film-based delivery system for vaccine administration. We reviewed the different types of new vaccines and vaccine formulations such as VLP based, liposome, bilosome, particulate, and summarized their suitability for use in a film dosage form. Quickly soluble film dosage form is the most optimized form of buccal administration. A film dosage form applied in the buccal cavity has several advantages: they can avoid first pass effect, they are easy to administer and prepare, and they are more cost effective. Since there is no first pass effect, only a small quantity of the vaccine is needed. Vaccines in their original form or in a nano or microparticulate form can be used in a film. The film can also be developed in multilayers to protect the vaccine from degradation by saliva or swallowing. Films are easy to prepare, administer, and can be used for systemic and local action. In addition, most of the current vaccines use mostly the parenteral route of administration, which has some major drawbacks such as poor induction of mucosal immunity, less patient compliant, less potent, high cost and cumbersome production process. Sublingual and buccal vaccine delivery can be good alternatives as they are easier to prepare and safer than parenteral administration routes. The buccal and sublingual administration have the advantage to produce both systemic and mucosal immunity.  

Downloads

Download data is not yet available.

Author Biographies

Mohammad Nasir Uddin, College of Pharmacy, Larkin University, Miami, FL, USA.

Associate Professor

Department of Pharmaceutical Sciences

College of Pharmacy

Larkin University

Miami, FL 33169

Amanda Allon, College of Pharmacy, Larkin University, Miami, FL, USA.

Student Pharmacist

College of Pharmacy

Larkin University

Miami, FL 33169

Monzurul A Roni, College of Medicine, University of Illinois, Peoria, IL; School of Pharmacy, Wingate University, Wingate, NC, USA.

Assistant Professor

Hampton University School of Pharmacy

Hampton, VA 23668

Samir Kouzi, College of Medicine, University of Illinois, Peoria, IL; School of Pharmacy, Wingate University, Wingate, NC, USA.

Professor

School of Pharmacy

Wingate University

Wingate, NC 28174

References

Bala R, Pawar P, Khanna S, et al. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67.

Office of Disease Prevention and Health Promotion. Immunization and Infectious Diseases. https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases.

Centers for Disease Control and Prevention. Ten great public health achievements--United States, 1900-1999. MMWR. Morbidity and mortality weekly report 1999;48.12: 241.

Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nature Reviews Drug Discovery. 2019;18: 19–40.

Brandtzaeg P. Function of mucosa-associated lymphoid tissue in antibody formation. Immunol Invest. 2010;39(4-5):303-355.

Amorij JP, Kersten GF, Saluja V, et al. Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release. 2012;161(2):363-376.

U.S. Department of Health and Human Services. https://www.vaccines.gov/basics/types/index.html.

National Institute of Allergy and Infectious Diseases. https://www.niaid.nih.gov/research/vaccine-types.

World Health Organization. Vaccine Safety Basics. Module 2: Types of Vaccine and Adverse reactions – Route of Administration; http://vaccine-safety-training.org/route-of-administration.html

Trindade ES, Safety profile of human papillomavirus vaccines. Rev Bras Patol Trato Genit Infer. 2012;2: 76–80.

Kang S, Kim KH, Kim YT, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo‐controlled trial in 176 Korean subjects. Int J Gynecol Cancer. 2008;18(5):1013-1019.

American Academy of Allergy Asthma & Immunology. What is the risk of Anaphylaxis after vaccination in children and adults? https://www.aaaai.org/global/latest-research-summaries/Current-JACI-Research/What-is-the-risk-of-anaphylaxis-after-vaccination.

Uddin MN. Progress in Human Papillomavirus (HPV) Vaccine Development. J Develop Drugs. 2013;2: 122.

Farris E, Brown DM, Ramer-Tait AE, Pannier AK. Micro-and nanoparticulates for DNA vaccine delivery. Exp Biol Med. 2016;241(9):919-929.

Yang B, Jeang J, Yang A. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10(11):3153-3164.

Beirne PV, Hennessy S, Cadogan SL, et al. Needle size for vaccination procedures in children and adolescents. Cochrane Database Syst Rev. 2015; 18(6); 11-20.

Sudhakar Y, Kuotsu K, Bandyopadhyay AK. Buccal bioadhesive drug delivery—a promising option for orally less efficient drugs. J Control Release. 2006;114(1):15-40.

Pelaseyed T, Bergström JH, Gustafsson JK, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev. 2014;260(1):8-20.

Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Del Rev. 2012;64(6):557-570.

Raza F, Zafar H, Zhu Y, Ren Y, Ullah A, Khan AU. A review on recent advances in stabilizing peptides/proteins upon fabrication in hydrogels from biodegradable polymers. Pharmaceutics. 2018;10: 1–21.

John B. Leiper; Fate of ingested fluids: factors affecting gastric emptying and intestinal absorption of beverages in humans, Nutrition Reviews. 2015: 73(2), 57–72.

Zhang L, Wang W, Wang S. Effect of vaccine administration modality on immunogenicity and efficacy. Expert Rev Vaccines. 2015;14(11):1509-23.

Vela Ramirez JE, Sharpe LA, Peppas NA. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev. 2017;114: 116-131.

Janeway CA, Travers P, Walport M, et al. Immunobiology: the immune system in health and disease. New York: Garland Pub.; 2001.

https://www.ncbi.nlm.nih.gov/books/NBK27169/

Chen K, Cerutti A. Vaccination strategies to promote mucosal antibody responses. Immunity. 2010;33(4):479-491.

Nguyen DN, Green JJ, Chan JM, et al. Polymeric materials for gene delivery and DNA vaccination. Adv Mater 2009; 21:847–867.

O’Hagan DT, Singh M, Ulmer JB. Microparticles for the delivery of DNA vaccines. Immunol Rev 2004; 199: 191–200.

Prabha S, Zhou W-Z, Panyam J, et al. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm 2002; 244:105–115.

Zhang XP, Li YD, Luo LL, et al. Astragalus saponins and liposome constitute an efficacious adjuvant formulation for cancer vaccines. Cancer Biother Radiopharm. 2018;33(1):25-31.

De Serrano LO, Burkhart DJ. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines. J Nanobiotechnology. 2017;15(1):83.

Liang R, Xie J, Li J, et al. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response. Biomaterials. 2017;149: 41-50.

Miao L, Yang Y, Yan M, Li Y, Zhao J, Guo J, Zheng D. Enhanced Immune Response to Rabies Viruses by the Use of a Liposome Adjuvant in Vaccines. Viral Immunol. 2017;30(10):727-733.

Lai C, Duan S, Ye F, et al. The enhanced antitumor-specific immune response with mannose-and CpG-ODN-coated liposomes delivering TRP2 peptide. Theranostics. 2018;8(6):1723.

Khademi F, Taheri RA, Momtazi-Borojeni AA, Farnoosh G, Johnston TP, Sahebkar A. Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines. Rev Physiol, Biochem Pharmacol. 2018;175: 47-69.

Uddin MN, Kouzi SA, Hussain MD. Strategies for developing oral vaccines for human papillomavirus (HPV) induced cancer using nanoparticle mediated delivery system. J Pharm Pharm Sci. 2015;18(2):220-234.

Reddy ST, Rehor A, Schmoekel HG, et al. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release. 2006;112(1):26–34.

Walter E, Dreher D, Kok M, et al. Hydrophilic poly(D,L-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J Control Release. 2001;76 (1–2):149–168.

Rice-Fichte AC, Arenas-Gambia AM, Kahl-McDonagh MM, et al. Polymeric particles in vaccine delivery. Reviews particle-based properties, such as surface chemistry and sizes that will affect antigen presentation and processing by APCs. Curr Opin Microbiol 2009; 13(1):106–112.

Thomasin C, Corradin G, Men Y, et al. Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-coglycolide) microspheres: importance of polymer degradation and antigen release for immune response. J Control Release. 1996; 41(1–2):131–145.

Mallapragada SK, Narasimhan B. Immunomodulatory biomaterials. Int J Pharm 2008; 364(2):265–271.

Slütter B, Soema PC, Ding Z, et al. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J Control Release. 2010;143(2):207–214.

O’Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev 1998; 34(2–3):305–320.

Hamdy S, Haddadi A, Hung RW, et al. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev. 2011; 63(10-11):943-955.

Mönkäre J, Pontier M, van Kampen EE, et al. Development of PLGA nanoparticle loaded dissolving microneedles and comparison with hollow microneedles in intradermal vaccine delivery. Eur J Pharm Biopharm. 2018;129: 111-121.

Bhowmik T, D’Souza B, Uddin MN, et al. Oral delivery of microparticles containing plasmid DNA encoding hepatitis-B surface antigen. J Drug Target. 2012;20(4):364-371.

Bielinska AU, Kukowska-Latallo JF, Baker Jr JR. The interaction of plasmid DNA with polyamidoamine dendrimers: mechanism of complex formation and analysis of alterations induced in nuclease sensitivity and transcriptional activity of the complexed DNA. Biochim Biophys Acta. 1997;1353(2):180-190.

Uddin MN. Virus-Like Particle: The Next Generation Vaccine? J Develop Drugs. 2014;3: 1

Roldao A, Mellado MC, Castilho LR, et al. Virus-like particles in vaccine development. Exp Rev Vaccin. 2010;9(10):1149-1176.

Zhao Q, Li S, Yu H, et al. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol. 2013;31(11):654-663.

Schiller JT, Hidesheim A. Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol. 2000;19(1-2):67-74.

Frey A, Neutra MR. Targeting of mucosal vaccines to Peyer's patch M cells. Behring Inst Mitt. 1997;98: 376-389.

Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89(24):12180-12184.

Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol. 1994;75(8):2075-2079.

Quan FS, Lee YT, Kim KH, et al. Progress in developing virus-like particle influenza vaccines. Exp Rev Vaccin. 2016;15(10):1281-1293.

Carter DM, Darby CA, Lefoley BC. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J Virol. 2016;90(9):4720-4734.

Carra JH, Martins KA, Schokman RD. A thermostable, chromatographically purified Ebola nano-VLP vaccine. J Transl Med. 2015;13(1):228.

Boigard H, Alimova A, Martin GR. Zika virus-like particle (VLP) based vaccine. PLoS Negl Trop Dis. 2017;11(5).

Reddy PC, Chaitanya KS, Rao YM. A review on bioadhesive buccal drug delivery systems: current status of formulation and evaluation methods. Daru. 2011;19(6):385.

Shojaei AH, Chang RK, Guo X. Systemic drug delivery via the buccal mucosal route. J Pharm Technol. 2001; 25(6):70-81.

Rojanasakul Y, Wang LY, Bhat M, et al. The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit. Pharm Res. 1992; 9:1029-1034.

Collins LMC, Dawes C. The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. J Dent Res. 1987; 66:1300-1302.

Lee JW, Park JH, Robinson JR. Bioadhesive-based dosage forms: the next generation. J Pharm Sci. 2000; 89:850-866.

Alur HH, Johnston TP, Mitra AK. Peptides and Proteins: Buccal Absorption. in: Swarbrick J, Boylan J.C, ed. Encyclopedia of Pharmaceutical Technology vol. 20 (3), Marcel Dekker Inc., New York, 2001, 193-218.

Gandhi RB, Robinson JR. Oral cavity as a site for bioadhesive drug delivery. Adv Drug Del Rev. 1994;13(1-2):43-74.

Galey WR, Lonsdale HK, Nacht S. The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. J Invest Dermatol. 1976; 67:713–717.

Kildsgaard J, Brimnes J, Jacobi H, et al. Sublingual immunotherapy in sensitized mice. Ann Allergy Asthma Immunol. 2007;98(4):366-372.

Agostinis F, Tellarini L, Canonica GW, et al. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy. 2005;60(1):133.

de Barros JM, Costabile A, Charalampopoulos D, et al. Evaluating and optimizing oral formulations of live bacterial vaccines using a gastro-small intestine model. Eur J Pharm Biopharm. 2016; 102:115-22.

Gala RP, Popescu C, Knipp GT, et al. Physicochemical and Preclinical Evaluation of a Novel Buccal Measles Vaccine. AAPS PharmSciTech. 2017;18(2):283-292.

Uddin MN. Alternative Vaccine Strategies for Cervical Cancer. J Develop Drugs. 2015; 4:2.

Hao J, Heng PW. Buccal delivery systems. Drug Dev Ind Pharmacy. 2003;29(8):821-832.

Hearnden V, Sankar V, Hull K, et al. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Del Rev. 2012;64(1):16-28.

Harde H, Agrawal AK, Jain S. Tetanus toxoid-loaded layer-by-layer nanoassemblies for efficient systemic, mucosal, and cellular immunostimulatory response following oral administration. Drug Deliv Transl Res. 2015;5(5):498-510.

Stephen R. Boden1 and A. Wesley Burks. Anaphylaxis: a history with emphasis on food allergy. Immunol Rev. 2011. 242(1): 247–257.

Borges AF, Silva C, Coelho JF, et al. Oral films: current status and future perspectives: I—galenical development and quality attributes. J Control Release. 2015;206: 1-9.

Amin PM, Gangurde AB, Alai PV. Oral film technology: challenges and future scope for pharmaceutical industry. Int J Pharm Pharm Res. 2015;3(3):184-203.

Haque SE, Sheela A. Development of polymer-bound fast-dissolving metformin buccal film with disintegrants. Int J Nanomed. 2015;10(Suppl 1):199.

Kraan H, Vrieling H, Czerkinsky C, et al. Buccal and sublingual vaccine delivery. J Control Release. 2014;190: 580-592.

Song JH, Nguyen HH, Cuburu N, et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proceedings of the National Academy of Sciences. 2008 Feb 5;105(5):1644-9.

Ferro V. Novel Approaches to Vaccine Research: Kerala (India). Research Signpost; 2011. Adjuvants and vaccine delivery systems; p. 199-222.

Thomas C, Rawat A, Hope-Weeks L, et al. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol Pharm. 2011;8(2):405-415.

Madhi SA, Kuwanda L, Cutland C, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis. 2005;40(10):1511-8.

Lu D, Garcia-Contreras L, Muttil P, et al. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J. 2010;12(3):338-347.

Muttil P, Prego C, Garcia-Contreras L, et al. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J. 2010;12(3):330-337.

Thomas C, Gupta V, Ahsan F. Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles. Pharm Res. 2010;27(5):905-919.

Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther. 2016;10: 483.

C Dinda S, Pattnaik G. Nanobiotechnology-based drug delivery in brain targeting. Curr Pharm Biotechnol. 2013;14(15):1264-1274.

Sun B, Xia T. Nanomaterial-based vaccine adjuvants. J Mater Chem B. 2016;4(33):5496-5509.

Hu Y, Hoerle R, Ehrich M, et al. Engineering the lipid layer of lipid–PLGA hybrid nanoparticles for enhanced in vitro cellular uptake and improved stability. Acta Biomater. 2015;28: 149-159.

Bharali DJ, Pradhan V, Elkin G, et al. Novel nanoparticles for the delivery of recombinant hepatitis B vaccine. Nanomedicine. 2008;4(4):311-317.

Wang J, Hu X, Xianga D, Nanoparticle drug delivery systems: an excellent carrier for tumor peptide vaccines. Drug Deliv. 2018; 25(1): 1319–1327.

Capron A, Riveau G, Grzych J-M, Boulanger D, et al. Development of a vaccine strategy against human and bovine schistosomiasis: background and update. Trop Geogr Med. 1994; 46:242–246.

de Barros JM, Scherer T, Charalampopoulos D, et al. A laminated polymer film formulation for enteric delivery of live vaccine and probiotic bacteria. J Pharm Sci. 2014;103(7):2022-2032.

Lundholm P, Asakura Y, Hinkula J, et al. Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA. Vaccine. 1999;17(15-16):2036-2042.

Downloads

Published

2019-08-05

How to Cite

Uddin, M. N., Allon, A., Roni, M. A., & Kouzi, S. (2019). Overview and Future Potential of Fast Dissolving Buccal Films as Drug Delivery System for Vaccines. Journal of Pharmacy & Pharmaceutical Sciences, 22(1), 388–406. https://doi.org/10.18433/jpps30528

Issue

Section

Review Articles